Matt Link resigned from the Board of Directors of FibroBiologics, Inc. effective July 2, 2026. On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D., a former NASA Astronaut and Professor at the University of Pittsburgh School of Medicine, as a Class III director. Dr. Rubins will also serve on the Audit, Compensation, and Governance and Nominating Committees until the 2029 annual meeting. FibroBiologics, Inc. is a biotechnology company.

FibroBiologics, Inc. entered into a Securities Purchase Agreement on June 25, 2026, for a private placement offering that raised gross proceeds of $3,000,000. The offering included pre-funded warrants to purchase 4,081,633 shares of common stock and warrants to purchase up to 8,163,266 shares at an exercise price of $0.735 per share. Net proceeds to the company were approximately $2.6 million. FibroBiologics, Inc. is a biotechnology company focused on the development and manufacture of biologics.

At its June 22, 2026, Annual Meeting, FibroBiologics, Inc. stockholders approved the 2026 Equity and Incentive Compensation Plan, which replaces the 2022 Stock Plan. The new plan provides 2,061,968 shares for equity-based compensation and includes evergreen provisions for annual share increases through 2036. Additionally, stockholders approved the issuance of up to 2,272,728 shares related to outstanding warrants from March 2026 Securities Purchase Agreements and 159,091 shares from a November 2025 engagement letter. Pete O’Heeron was elected as a Class III director, and the appointment of WithumSmith+Brown, PC as the independent auditor was ratified. FibroBiologics, Inc. is a biotechnology company focused on developing therapeutic biologics.